SCHEMBL4038539

SCHEMBL4038539

O=C(NC1CCCCC1)C(C1CCCCC1)C1(c2ccc(Cl)s2)Nc2cc(F)c(F)cc2N1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.41
NPC1 O15118 5/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
NR1H4 Q96RI1 5/20 0.39
KCNH2 Q12809 4/20 0.39
CYP3A4 P08684 3/20 0.39
CYP2D6 P10635 2/20 0.39
CYP2C9 P11712 2/20 0.39
KMT2A Q03164 4/20 0.39
GAA P10253 2/20 0.39
HTT P42858 2/20 0.39
MEN1 O00255 2/20 0.39
POLB P06746 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
EPHX2 P34913 2/20 0.36
LMNA P02545 1/20 0.35
HSD11B1 P28845 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4037758 0.95 CYP3A4 (0.41) RAB9ANPC1SMN1; SMN2NR1H4KCNH2
SCHEMBL4037433 0.89 KMT2A (0.41) RAB9ANPC1SMN1; SMN2NR1H4CYP3A4
SCHEMBL4040574 0.89 KMT2A (0.41) RAB9ANPC1SMN1; SMN2NR1H4CYP3A4
SCHEMBL4035080 0.85 NR1H4 (0.41) RAB9ANPC1SMN1; SMN2NR1H4CYP3A4
SCHEMBL4037381 0.85 NR1H4 (0.41) RAB9ANPC1SMN1; SMN2NR1H4CYP3A4
SCHEMBL4034314 0.85 NR1H4 (0.41) RAB9ANPC1SMN1; SMN2NR1H4CYP3A4
SCHEMBL4044322 0.85 NR1H4 (0.41) RAB9ANPC1SMN1; SMN2NR1H4CYP3A4
SCHEMBL4035029 0.83 NR1H4 (0.47) RAB9ANPC1SMN1; SMN2NR1H4KCNH2
SCHEMBL4040844 0.83 NR1H4 (0.47) RAB9ANPC1SMN1; SMN2NR1H4KCNH2
SCHEMBL4038088 0.81 RAB9A (0.44) RAB9ANPC1SMN1; SMN2NR1H4KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2038259-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F.HOFFMANN-LA ROCHE AG (CH) 2009-03-25 EP claimed
WO-2008000643-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F. HOFFMANN-LA ROCHE AG (CH) 2008-01-03 WO claimed
EP-3043865-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) 2016-07-20 EP disclosed
WO-2015036442-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2015-03-19 WO disclosed
EP-2038259-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F.HOFFMANN-LA ROCHE AG (CH) 2009-03-25 EP disclosed
WO-2008000643-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F. HOFFMANN-LA ROCHE AG (CH) 2008-01-03 WO disclosed